


OUR SUPPORT FOR YOU

# DEVELOPABILITY ASSESSMENT FOR ANTIBODIES



Late-stage failures in drug development often result from advancing molecules that are difficult to formulate or manufacture. Coriolis Pharma addresses this challenge by combining laboratory-based and *in silico* developability assessments to provide early insights into molecule characteristics and potential liabilities, optimize formulations, and mitigate risks. By streamlining decision-making processes and predicting stability and manufacturability issues early on, Coriolis helps developers reduce costs, accelerate timelines, and improve the likelihood of success from discovery to commercialization.


## Accelerating Drug Development


Coriolis Pharma offers its clients a cutting-edge developability assessment platform, tailored for modern biologics drug development challenges.

This innovative service empowers biopharma companies with early-stage programs to make informed decisions quickly and efficiently.

### Key Features

- Evaluates mAb candidates with minimal sample quantities (as low as single-digit milligrams)
- Combines unique analytical methods and *in silico* approaches
- Enables early decision-making, saving time and resources
- Reduces the risk of late-stage failures
- Different packages based on your development stage and goal





## Our Approach

Choose from three developability packages with different focus:

- Candidate selection
- High concentration suitability
- Formulation sensitivity

## Your Benefits

- You will unlock the full potential of your mAb candidates.
- You will make smarter decisions earlier in the development process and streamline your pipeline.
- You will accelerate your path to successful drug products for human application.
- You will start your journey with a service provider who does not leave you alone afterwards, but can continue to accompany your development until commercial success.

## Further Modalities

You are not working on a mAb, but on a related molecule, a different kind of therapeutic protein or a peptide? Reach out to us and see whether the Coriolis developability platform can also be applied to your molecule.

## Why Choose Coriolis?

- Full lifecycle support with the end goal in mind from preclinical to commercial under R&D and GMP
- Development of drug products designed for global launches, specifically meeting the requirements of the FDA, EMA and Japanese regulatory standards
- Client-focused collaboration with an independent service provider, offering dedicated attention to your specific project, molecule and development phase
- Bridging the gap between discovery phase and clinical development
- Scientifically robust approach for antibody candidate selection with the best chance of becoming a drug product
- Novel innovative methods published from Coriolis' team and scientific advisors to efficiently assess your antibody's biophysical properties
- Seamless development of your antibody drug product formulation for first clinical application ensuring a risk-appropriate approach
- Guidance and support until late-stage drug development through to market authorization
- Representatives in close proximity to you and your team with offices in the EU and USA

### Headquarters

Fraunhoferstraße 18 b  
82152 Martinsried  
Germany  
Phone: +49 89 41 77 60 – 0

### U.S. Commercial Organization

455 E Eisenhower Pkwy  
Suite 300, #1130  
Ann Arbor, MI 48108  
United States  
Phone: +1 (256) 400-4491



[www.coriolis-pharma.com/contact](http://www.coriolis-pharma.com/contact)